Genmab — Februar 2017
-
Reuters: Biotekselskab gør klar til at afværge overtagelse
Et amerikansk biotekselskab, der angiveligt tiltrækker sig interesse fra flere store medicinalaktører, herunder franske Sanofi, konsulterer nu med investeringsbanker om dets muligheder i den forbindelse. Det skriver Reuters.
(medwatch.dk)
-
https://www.winterflood.com/home/index.html Så har vi en ny spiller på banen som handler for institutionelle investorer, formueforvaltere og andet godtfolk. De har indtil videre købt svimlende 15 aktier:-)
-
bibob -
Actelion siger jeg bare!
God præcedens for at Tesaro ikke er for dyr, hvis BP virkelig vil ha' den -
Well said E.L. it's fascinating. I think the lessons here are 1) markets have trouble valuating biotech’s, it’s just too complex to really understand why certain companies will succeed while others will not and 2) and this is a scary one but oh so true, small biotech’s have the chance to be manipulated by the big investment banks (GS), over and over again.
-
This scares away investors. But at a certain moment the value creation becomes too obvious, the market cap will rise and then there’s an inflection point at which the stock price can’t be significantly manipulated anymore.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind